AU2003276220A1 - Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) - Google Patents
Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)Info
- Publication number
- AU2003276220A1 AU2003276220A1 AU2003276220A AU2003276220A AU2003276220A1 AU 2003276220 A1 AU2003276220 A1 AU 2003276220A1 AU 2003276220 A AU2003276220 A AU 2003276220A AU 2003276220 A AU2003276220 A AU 2003276220A AU 2003276220 A1 AU2003276220 A1 AU 2003276220A1
- Authority
- AU
- Australia
- Prior art keywords
- pde2a
- therapeutics
- diagnostics
- diseases associated
- human phosphodiesterase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02025505 | 2002-11-13 | ||
| EP02025505.5 | 2002-11-13 | ||
| PCT/EP2003/012124 WO2004044234A1 (en) | 2002-11-13 | 2003-10-31 | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003276220A1 true AU2003276220A1 (en) | 2004-06-03 |
Family
ID=32309338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003276220A Abandoned AU2003276220A1 (en) | 2002-11-13 | 2003-10-31 | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1597386A1 (en) |
| AU (1) | AU2003276220A1 (en) |
| WO (1) | WO2004044234A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| ATE438403T1 (en) * | 2004-08-19 | 2009-08-15 | Switch Biotech Llc | USE OF A PDE5 INHIBITOR TO TREAT AND PREVENT HYPOPIGMENTATION DISORDERS |
| CA2619779C (en) | 2004-08-19 | 2013-03-12 | Switch Biotech Ag | Use of a pde5 inhibitor for treating and preventing hypopigmentary disorders |
| DE102006048693A1 (en) * | 2006-10-14 | 2008-04-17 | Bayer Healthcare Ag | Inhibition of PDE2A |
| CA2869730A1 (en) | 2012-04-25 | 2013-10-31 | Takeda Pharmaceutical Company Limited | Nitrogenated heterocyclic compound |
| WO2014010732A1 (en) | 2012-07-13 | 2014-01-16 | 武田薬品工業株式会社 | Heterocyclic compound |
| WO2014142255A1 (en) | 2013-03-14 | 2014-09-18 | 武田薬品工業株式会社 | Heterocyclic compound |
| JP6427491B2 (en) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | Heterocyclic compounds |
| JP6411342B2 (en) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | Amide compounds |
| HRP20212035T1 (en) | 2014-04-23 | 2022-04-01 | Dart Neuroscience Llc | Compositions containing substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors |
| EP3215508A1 (en) | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted 5-methyl-[1, 2, 4]triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors |
| EP3562828A1 (en) | 2016-12-28 | 2019-11-06 | Dart NeuroScience LLC | Substituted pyrazolopyrimidinone compounds as pde2 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL132366A0 (en) * | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
| US6376225B1 (en) * | 2001-01-05 | 2002-04-23 | Pe Corporation (Ny) | Isolated human phosphodiesterase proteins, nucleic acid molecules encoding human phosphodiesterase proteins, and uses thereof |
| US6465494B1 (en) * | 2001-08-24 | 2002-10-15 | Cell Pathways, Inc. | Methods for treatment of cystic fibrosis |
-
2003
- 2003-10-31 AU AU2003276220A patent/AU2003276220A1/en not_active Abandoned
- 2003-10-31 WO PCT/EP2003/012124 patent/WO2004044234A1/en not_active Application Discontinuation
- 2003-10-31 EP EP03810957A patent/EP1597386A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1597386A1 (en) | 2005-11-23 |
| WO2004044234A1 (en) | 2004-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003251471A1 (en) | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5) | |
| PL1603915T3 (en) | SUBSTITUTED 8 -PYRIDINYL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE AND 8 -PYRIMIDIN YL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES | |
| AU2003276220A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) | |
| AU2003301894A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) | |
| AU2003238339A1 (en) | Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor | |
| AU2003229735A1 (en) | Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr) | |
| AU2003276136A1 (en) | Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1) | |
| AU2003283303A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b) | |
| AU2003274083A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a) | |
| AU2003205627A1 (en) | Diagnostics and therapeutics for diseases associated with gpr72 | |
| AU2003267380A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a) | |
| AU2003279361A1 (en) | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b) | |
| AU2003283427A1 (en) | Diagnostics and therapeutics for diseases associated with phosphodiesterase 9a1 (pde9a1) | |
| AU2003294728A1 (en) | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 9a2 (PDE9a2) | |
| AU2003289894A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 9a4 (pde9a4) | |
| AU2003288158A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4c (pde4c) | |
| AU2003279323A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b) | |
| AU2003288171A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 9a3 (pde9a3) | |
| AU2003282087A1 (en) | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A1 (PDE7a1) | |
| AU2003252075A1 (en) | Human immunosuppressive protein | |
| AU2003276187A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8a (pde8a) | |
| AU2003283302A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a1 (pde11a1) | |
| AU2003279322A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a3 (pde11a3) | |
| AU2003274082A1 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4a (pde4a) | |
| AU2003301913A1 (en) | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A2 (PDE7a2) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |